Type1diabetes
Conditions
Keywords
fear of hypoglycemia, self-management, glycemic control, glycemic variability
Brief summary
This study is being conducted to determine the feasibility of a cognitive behavioral therapy intervention to reduce fear of hypoglycemia and improve glucose levels in young adults with type 1 diabetes.
Detailed description
In persons with type 1 diabetes (T1DM), iatrogenic hypoglycemia is the major limiting factor in achieving optimal blood glucose control. All persons with T1DM are at risk for hypoglycemia (blood glucose level \< 70 mg/dl), which is life-threatening and has serious physical symptoms and psychological sequelae that lead to profound fear of future hypoglycemic events. This fear results in greater glucose variability (the intra-day fluctuations in blood glucose), due to under- or overcompensation of food intake, insulin dosing, or physical activity, as well as anxiety, depression, and reduced quality of life. Greater glycemic variability (GV) is associated with a higher risk of hypoglycemia and diabetes complications. Young adults are particularly at risk because they report greater FOH and have poorer glycemic control. A major gap exists in how to manage FOH as a crucial component of diabetes self-care. Our overall objective is to reduce FOH and improve diabetes self-management, glycemic control, and variability in young adults with T1DM. We specifically aim to: (1) Determine the feasibility of an 8-week CBT-based intervention to reduce FOH and (2) obtain means and standard deviations of group differences from baseline to program completion on the outcomes of FOH, self-management, glycemic control and glycemic variability in young adults with T1DM who experience FOH. To achieve these aims, we propose a randomized control pilot trial in 10 young adults aged 18 to 30 years with T1DM. Participants will be screened for FOH levels. Eligible subjects will be randomized to the intervention (Fear Reduction Efficacy Evaluation \[FREE\]) program or attention control group. A 1-week run-in phase is planned, with baseline measures of FOH and 24-hour real-time continuous glucose monitoring recordings (RT-CGM) to calculate GV for both groups. The intervention group will participate in eight weekly one-hour sessions using a cognitive behavioral therapy (CBT) and exposure treatment for specific fears. RT-CGM and a daily FOH diary will be used as feedback cues. The control group will wear a 24-hour RT-CGM device during the same 8-week period and return for weekly RT-CGM site changes by study staff. At completion, FOH will be measured, and RT-CGM recordings will be analyzed to determine within-group and between-group differences. The findings from this proposed study will serve as the foundation for a larger clinical trial to reduce FOH and improve self-management, glycemic control, and variability. Meeting these goals will have important clinical implications to reduce diabetes complications and improve quality of life in young adults with T1DM.
Interventions
Cognitive behavioral therapy with real-time continuous glucose monitoring.
Sponsors
Study design
Intervention model description
Randomized controlled trial
Eligibility
Inclusion criteria
* type 1 diabetes ≥ 1 year * receive medical care from an endocrinologist * use insulin pump therapy * have self-reported fear of hypoglycemia (FOH;screening questionnaire)
Exclusion criteria
* pregnant or breastfeeding * actively treated for a mental health condition * have a co-existing chronic illness or taking medications (excluding insulin) that may influence diabetes self-management or glycemic variability
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hypoglycemia Fear Scale Score (HFS_2) | 12 weeks | A reliable and valid psychological scale. It is a 5-point Likert scale \[0-4\], that is summed for a single total continuous scale score. Scores may range from 0-72. Higher numbers indicate greater fear of hypoglycemia. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diabetes Self-Management Questionnaire Scale Score (DSMQ) | 12 weeks | A reliable and valid behavioral scale, provides total continuous scale score, ranging from 0-81, higher numbers indicate better self-management. |
| Glycemic Control, the Average Blood Glucose Over a 2-3 Month Period of Time. | 12 weeks | Hemoglobin A1c represents the average blood glucose over a 2-3 month period and is an index of glycemic control. The American Diabetes Association recommends a hemoglobin A1C below 7% for most people with diabetes. Higher percentages indicate higher average blood glucose levels. |
| Glycemic Variability | 8 weeks | Twenty-four hour fluctuations in glucose measured by a continuous glucose monitor that provides interstitial glucose readings every 5 minutes. This is a continuous measure. A higher standard deviation reflects greater glycemic variability. |
Countries
United States
Participant flow
Recruitment details
Subjects will be recruited through Chicago metropolitan area university medical centers, local diabetes websites, and organizations using flyers, e-announcements, and recruitment letters.
Participants by arm
| Arm | Count |
|---|---|
| FREE Group Cognitive behavioral therapy intervention with real-time continuous glucose monitoring.
FREE: Cognitive behavioral therapy with real-time continuous glucose monitoring. | 5 |
| Control Group Real-time continuous glucose monitoring | 5 |
| Total | 10 |
Baseline characteristics
| Characteristic | FREE Group | Total | Control Group |
|---|---|---|---|
| A1C | 7.2 percentage STANDARD_DEVIATION 1.29 | 7.58 percentage STANDARD_DEVIATION 1.28 | 7.96 percentage STANDARD_DEVIATION 1.3 |
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 5 Participants | 10 Participants | 5 Participants |
| Diabetes Self-management Questionnaire | 56.2 units on a scale STANDARD_DEVIATION 13.2 | 54.2 units on a scale STANDARD_DEVIATION 11.9 | 52.2 units on a scale STANDARD_DEVIATION 11.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants | 10 Participants | 5 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Glycemic variability | 66.04 mg/dL STANDARD_DEVIATION 16.7 | 71.03 mg/dL STANDARD_DEVIATION 15.9 | 79.3 mg/dL STANDARD_DEVIATION 12.9 |
| Hypoglycemia Fear Survey II - Worry subscale | 36.6 units on a scale STANDARD_DEVIATION 18.4 | 37.7 units on a scale STANDARD_DEVIATION 12.9 | 38.8 units on a scale STANDARD_DEVIATION 6 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 5 Participants | 10 Participants | 5 Participants |
| Region of Enrollment United States | 5 participants | 10 participants | 5 participants |
| Sex: Female, Male Female | 2 Participants | 6 Participants | 4 Participants |
| Sex: Female, Male Male | 3 Participants | 4 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 5 | 0 / 5 |
| other Total, other adverse events | 0 / 5 | 0 / 5 |
| serious Total, serious adverse events | 0 / 5 | 0 / 5 |
Outcome results
Hypoglycemia Fear Scale Score (HFS_2)
A reliable and valid psychological scale. It is a 5-point Likert scale \[0-4\], that is summed for a single total continuous scale score. Scores may range from 0-72. Higher numbers indicate greater fear of hypoglycemia.
Time frame: 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| FREE Group | Hypoglycemia Fear Scale Score (HFS_2) | 21.4 units on a scale | Standard Deviation 10.9 |
| Control Group | Hypoglycemia Fear Scale Score (HFS_2) | 38.6 units on a scale | Standard Deviation 8.2 |
Diabetes Self-Management Questionnaire Scale Score (DSMQ)
A reliable and valid behavioral scale, provides total continuous scale score, ranging from 0-81, higher numbers indicate better self-management.
Time frame: 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| FREE Group | Diabetes Self-Management Questionnaire Scale Score (DSMQ) | 58.7 units on a scale | Standard Deviation 12.6 |
| Control Group | Diabetes Self-Management Questionnaire Scale Score (DSMQ) | 50.6 units on a scale | Standard Deviation 12.1 |
Glycemic Control, the Average Blood Glucose Over a 2-3 Month Period of Time.
Hemoglobin A1c represents the average blood glucose over a 2-3 month period and is an index of glycemic control. The American Diabetes Association recommends a hemoglobin A1C below 7% for most people with diabetes. Higher percentages indicate higher average blood glucose levels.
Time frame: 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| FREE Group | Glycemic Control, the Average Blood Glucose Over a 2-3 Month Period of Time. | 6.94 percentage | Standard Deviation 1.29 |
| Control Group | Glycemic Control, the Average Blood Glucose Over a 2-3 Month Period of Time. | 7.66 percentage | Standard Deviation 1.02 |
Glycemic Variability
Twenty-four hour fluctuations in glucose measured by a continuous glucose monitor that provides interstitial glucose readings every 5 minutes. This is a continuous measure. A higher standard deviation reflects greater glycemic variability.
Time frame: 8 weeks
Population: Same as above
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| FREE Group | Glycemic Variability | 73.0 mg/dL | Standard Deviation 13.8 |
| Control Group | Glycemic Variability | 73.3 mg/dL | Standard Deviation 11.8 |